IP Library Granted Patent US 8,716,283
Granted Patent B2
US 8,716,283 · App. 12/742,043 · Granted May 6, 2014

Type III secretion inhibitors, analogs and uses thereof

Inventors: Jon Goguen (Holden, MA); Ning Pan (Boylston, MA); Kyungae Lee (Newton, MA)
Assignees: University of Massachusetts; President and Fellows of Harvard College
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,716,283
App. No.
12/742,043
Granted
May 6, 2014
Kind
B2
Abstract

The invention, in some aspects, relates to compounds and compositions useful for inhibiting Type III secretion systems in pathogenic bacteria, such as Yersinia Pestis . In some aspects, the invention relates to methods for discovering inhibitors of the Type III secretion system and uses of such inhibitors in the treatment and prevention of disease.

Claims (42)

1. A method for inhibiting activity of a type III secretion system of a bacterium, comprising contacting a bacterium having a type III secretion system with an effective amount of at least one compound selected from the formula:

and a pharmaceutically acceptable salt thereof,

wherein:

R1 is selected from the group consisting of:

—O—(C1-C5)alkyl,

—NH—(C1-C5)alkyl,

—NH 2 , and

—OH, and

R2 is

wherein:

R3 and R4 are joined as a five- or six-member heterocyclic ring that may be further substituted at any one position with —CO—O—(C1-C5)alkyl or (C1-C5)alkyl, or

R3 is —H or —(C1-C5)alkyl and

R4 is selected from the group consisting of:

—(C1-C5)alkyl,

—(C3-C8)cycloalkyl,

—(C1-C5)alkyl-O—(C1-C5)alkyl,

—(C1-C5)alkyl-hydroxyl,

-phenyl, and

—(C1-C5)alkyl-phenyl,

wherein the phenyl group may be independently substituted at one, two, or three positions with —(C1-C5)alkyl or -halogen, and

R5 is selected from the group consisting of:

—(C1-C5)alkyl,

—(C3-C8)cycloalkyl,

-phenyl, and

—(C1-C5)alkyl-phenyl,

wherein the phenyl group may be substituted at one, two, or three positions with a substituent independently selected from the group consisting of:

—(C1-C5)alkyl,

—O—(C1-C5)alkyl,

-halogen,

—NO 2 ,

—CF 3 , and

—OCF 3 .

2. The method of claim 1 , wherein the at least one compound has a structure selected from the group consisting of:

3. The method of claim 1 , wherein the bacterium is a Yersinia species.

4. The method of claim 3 , wherein the Yersinia species is Yersinia pestis, Yersinia pseudotuberculosis , or Yersinia enterocolitica.

5. The method of claim 1 , wherein the bacterium is selected from the group consisting of: Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Salmonella enterica, Escherichia coli, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Pseudomonas aeruginosa, Burkholderia pseudomallei, Vibrio parahaemolyticus, Vibrio cholerae, Chlamydia trachomatis, Chlamydia pneumoniae , and Chlamydia psittaci.

6. The method of claim 1 , wherein the bacterium is in a subject.

7. The method of claim 6 , wherein the subject has a disease, or is at risk of a disease, caused by the bacterium.

8. The method of claim 7 , wherein the disease is selected from the group consisting of: bubonic plague, pneumonic plague, septicemic plague, enterocolitis, mesenteric lymphadenitis, typhlitis, typhoid-like disease, enteric fever, intestinal inflammation, bacteremia, septicemia, bloody diarrhea, renal failure, septic shock, bacillary dysentery (shigellosis), sporadic dysentery, whooping cough, kennel cough, atrophic rhinitis, respiratory illness, pneumonia, chronic airway infection, urinary tract infection, clinical infections, melioidosis, noninflammatory secretory diarrhea, inflammatory diarrhea, sexually transmitted infection, and psittacosis.

9. The method of claim 6 , wherein the subject is a human.

10. The method of claim 1 , wherein the bacterium is a biowarfare agent.

11. The method of claim 1 , wherein if R1 is —OH, then R5 is not

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 25, 2014
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033817/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: GOGUEN, JON; PAN, NING
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 025146/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2010
From: LEE, KYUNGAE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 024670/0662 →
CONFIRMATORY LICENSE Recorded Jun 10, 2010
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024512/0946 →
Continuity (4)
Continuation In Part PCTUS2008012610 · Nov 7, 2008
Provisional Application 61072712 · Apr 1, 2008
Provisional Application 61002316 · Nov 7, 2007
Related Publication 20110034463A1 · Feb 10, 2011